{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:24:52Z","timestamp":1793381092338,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.ctrv.2010.04.003","type":"journal-article","created":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T05:21:27Z","timestamp":1274160087000},"page":"615-620","source":"Crossref","is-referenced-by-count":109,"title":["Metastasis and bone loss: Advancing treatment and prevention"],"prefix":"10.1016","volume":"36","author":[{"given":"Robert E.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. David","family":"Roodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"Guise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon F.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Cl\u00e9zardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter I.","family":"Croucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Gralow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingunn","family":"Holen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Mundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Suva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2010.04.003_bib1","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI118947","article-title":"Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis","volume":"98","author":"Guise","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2010.04.003_bib2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.cell.2006.06.044","article-title":"Matrix elasticity directs stem cell lineage specification","volume":"126","author":"Engler","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2010.04.003_bib3","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1158\/0008-5472.CAN-06-0452","article-title":"The hedgegog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastaic human breast cancer cells","volume":"66","author":"Sterling","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib4","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2010.04.003_bib5","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2010.04.003_bib6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib7","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2007-03-077685","article-title":"Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo","volume":"111","author":"Edwards","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2010.04.003_bib8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1138\/20090381","article-title":"Insights into the antitumor effects of BPs from preclinical models and potential clinical implications","volume":"6","author":"Cl\u00e9zardin","year":"2009","journal-title":"IBMS BoneKE"},{"key":"10.1016\/j.ctrv.2010.04.003_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canlet.2007.07.007","article-title":"BPs in cancer therapy","volume":"257","author":"Stresing","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2010.04.003_bib10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of BPs in experimental breast cancer bone metastasis","volume":"99","author":"Daubin\u00e9","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2010.04.003_bib11","doi-asserted-by":"crossref","first-page":"8945","DOI":"10.1158\/0008-5472.CAN-08-2195","article-title":"Lowering bone mineral affinity of BPs as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo","volume":"68","author":"Fournier","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2010.04.003_bib13","first-page":"2572","article-title":"Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy","volume":"61","author":"Oyajobi","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib14","first-page":"287","article-title":"Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma","volume":"63","author":"Vanderkerken","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2010.04.003_bib16","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","article-title":"Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease","volume":"108","author":"Choi","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2010.04.003_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10585-006-9038-6","article-title":"Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model","volume":"23","author":"Menu","year":"2006","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ctrv.2010.04.003_bib18","first-page":"4040","article-title":"An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone-related protein in bone metastasis","volume":"56","author":"Iguchi","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1172\/JCI3523","article-title":"TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development","volume":"103","author":"Yin","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2010.04.003_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1349-7006.2006.00357.x","article-title":"Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line","volume":"98","author":"Ehata","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2010.04.003_bib21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1158\/0008-5472.CAN-08-3249","article-title":"Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice","volume":"69","author":"Sung","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib22","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","article-title":"Cathepsin K inhibitors as treatment of bone metastasis","volume":"67","author":"Le Gall","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/jpet.106.102004","article-title":"Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice. Implications for therapy","volume":"318","author":"Rucci","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ctrv.2010.04.003_bib24","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1158\/0008-5472.CAN-09-0354","article-title":"Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis","volume":"69","author":"Ports","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib25","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.1830978100","article-title":"A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases","volume":"100","author":"Yin","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2010.04.003_bib26","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1158\/0008-5472.CAN-06-4499","article-title":"Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases","volume":"67","author":"Zhao","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2174\/156800909789760339","article-title":"Anti-tumour effects of bisphosphonates \u2013 what have we learned from in vivo models?","volume":"9","author":"Brown","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ctrv.2010.04.003_bib28","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI31581","article-title":"The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development","volume":"117","author":"Wang","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2010.04.003_bib29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1182\/blood-2009-08-237628","article-title":"Osteoclasts are important for bone angiogenesis","volume":"115","author":"Cackowski","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2010.04.003_bib30","first-page":"46S","article-title":"Effect of zoledroninc acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer","volume":"26","author":"Aft","year":"2008","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2010.04.003_bib31","first-page":"20S","article-title":"Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow","volume":"26","author":"Lin","year":"2008","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2010.04.003_bib32","first-page":"S40","article-title":"Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer","volume":"206","author":"Rack","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2010.04.003_bib33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2010.04.003_bib34","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse, improved survival with oral clodronate for adjuvant treatment of operable breast cancer","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patient: 5-year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2010.04.003_bib36","first-page":"9s","article-title":"Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastses to bone marrow \u2013 longtime followup","volume":"22","author":"Jaschke","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2010.04.003_bib37","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/sj.bjc.6603661","article-title":"Meta-analysis of clodronate and breast cancer survival","volume":"96","author":"Ha","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2010.04.003_bib38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2010.04.003_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2010.04.003_bib40","unstructured":"Stopeck A, Body JJ, Fujimawara Y, et al. Denosumab demonstrates superiority over Zometa(R) in delay of complications due to bone metastases in advanced breast cancer patients ECCO\/ESMO; 2009 [abstract 2LBA]."},{"key":"10.1016\/j.ctrv.2010.04.003_bib41","doi-asserted-by":"crossref","unstructured":"Henry D, von Moos R, Vadhan-Raj V, et al. A double-blind randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (exclusing breast and prostate cancer) or multiple myeloma. ECCO\/ESMO; 2009 [abstract 20LBA].","DOI":"10.1016\/S1359-6349(09)72055-5"},{"key":"10.1016\/j.ctrv.2010.04.003_bib42","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/jco.2008.26.15_suppl.1023","article-title":"Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer, established bone metastases in a 4-week, double-blind, randomized controlled trial","volume":"26","author":"Jensen","year":"2008","journal-title":"J Clin Oncol ASCO Proceedings"},{"key":"10.1016\/j.ctrv.2010.04.003_bib43","doi-asserted-by":"crossref","first-page":"6291s","DOI":"10.1158\/1078-0432.CCR-06-0991","article-title":"Src inhibitors in metastatic bone disease","volume":"12","author":"Boyce","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2010.04.003_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2474-3-11","article-title":"The impact of incident vertebral, non-vertebral fractures on health related quality of life in postmenopausal women","volume":"3","author":"Adachi","year":"2002","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.ctrv.2010.04.003_bib46","first-page":"S187","article-title":"The need for DXA assessment of breast cancer patients following 5 years tamoxifen prior to starting an aromatase inhibitor","volume":"100","author":"Whannel","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2010.04.003_bib47","first-page":"69","article-title":"The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST","author":"Eidtmann","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2010.04.003_bib49","unstructured":"Lombarto AL, Frassoldati A, Paija O, et al. Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. In: 2009 ASCO Breast Cancer Symposium [abstract 213]."},{"key":"10.1016\/j.ctrv.2010.04.003_bib50","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2010.04.003_bib51","first-page":"S37","article-title":"The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis","volume":"106","author":"Van Poznak","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2010.04.003_bib52","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2010.04.003_bib53","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","article-title":"Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study","volume":"118","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2010.04.003_bib54","doi-asserted-by":"crossref","unstructured":"Logman F, Heeg B., Botteman M, et al. Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: application to the United Kingdom. ECCO; September 2007 [abstract 1146].","DOI":"10.1016\/S1359-6349(07)70665-1"},{"key":"10.1016\/j.ctrv.2010.04.003_bib55","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2010.04.003_bib56","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2010.04.003_bib57","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2010.04.003_bib58","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2010.04.003_bib59","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ctrv.2010.04.003_bib60","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","article-title":"Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study","volume":"179","author":"Smith","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2010.04.003_bib61","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737210000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737210000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T19:58:12Z","timestamp":1591300692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737210000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0305737210000800"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2010.04.003","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}